Skip to content

Ardelyx ARDX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$847K-82.6%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.39M+253%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$23.6M-26.5%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$713K-92.3%
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$4.06M-97.9%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$2.08M+28.4%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's stock issuance proceeds?
Ardelyx (ARDX) reported stock issuance proceeds of $5.44M in Q1 2026.
How has Ardelyx's stock issuance proceeds changed year-over-year?
Ardelyx's stock issuance proceeds increased by 267.2% year-over-year, from $1.48M to $5.44M.
What is the long-term trend for Ardelyx's stock issuance proceeds?
Over 4 years (2021 to 2025), Ardelyx's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $101.15M to $0.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.